

## CMV: Test of New Drug in Late Stage Begins; the CBCD Reviews a Report

New drug trials for brincidofovir for the prevention of cytomegalovirus (CMV) disease in kidney transplant recipients have begun. (1)


ROCHESTER, NY, UNITED STATES, October 28, 2015 /EINPresswire.com/ --

"Infected with the cytomegalovirus (CMV)? The CBCD recommends <u>Gene-Eden-VIR</u> or <u>Novirin</u>." – Greg Bennett, CBCD

Two separate phase 3 trials have begun to test the effectiveness of an investigational new drug called brincidofovir. The drug is designed to fight against the human cytomegalovirus (CMV), and other viruses. The late stage trials are being conducted by the drug development company, Chimerix (Nasdaq: CMRX). (1)

The Center for the Biology of Chronic Disease (CBCD) is encouraged by the efforts of the Chimerix researchers, since an easy to use, effective drug against CMV would be a medical breakthrough. In fact, such a drug is needed since, as the CDC notes, "CMV is a common virus that infects people of all ages. Most CMV infections are 'silent,' meaning most people who are infected with CMV have no signs or symptoms. However, CMV can cause disease in people with a weakened immune system and in babies infected before birth." (2) However, the Center reminds the public that it takes time before investigational drugs gain FDA approval, and many drugs fail





during the testing period. Therefore, the Center recommends that individuals infected with the CMV take Gene-Eden-VIR or Novirin against the latent cytomegalovirus. The formula of these natural antiviral products was designed to help the immune system target latent viruses.

clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the herpes family of viruses, including the human cytomegalovirus (CMV). The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the CMV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that, "we observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

http://www.gene-eden-vir.com

and

## http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

Regarding the phase 3 trials conducted by Chimerix, it should be noted that the company has not released cost information ... (but) ... as of June 30, the company had \$130 million in cash and equivalents." (1) A phase 3 trial can be expensive, but is typically the last major stop before a company submits a new drug application with the U.S. Food and Drug Administration." (1)

What current treatments are available against the cytomegalovirus?

"Several drugs are approved for the treatment of CMV infections in immunocompromised individuals. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. However, the use of these drugs in immunocompetent individuals is limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance." (3) There are also two natural CMV remedies with a clinically proven formula.

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure for conditions caused by CMV. However, two clinical studies showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was designed to help the immune system target the latent virus.

The CBCD believes that these facts, combined with the medical evidence presented above, indicate the need to target latent viruses like CMV. "We recommend that infected individuals talk to their doctors about Gene-Eden-VIR or Novirin." – Greg Bennett, CBCD

Find us on Facebook here: <a href="https://www.facebook.com/GeneEdenVIR">https://www.facebook.com/GeneEdenVIR</a>

Follow us Twitter here: @HananPolansky

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

## References:

- (1) deBruyn, J. "With eyes on FDA, Durham drug developer tests drug in late-stage trial" Published October 23, 2015. Bizjournals.com
- (2) CDC.gov "Cytomegalovirus (CMV) and Congenital CMV Infection" Page last updated: July 28, 2010
- (3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 <a href="http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VCfZypSSz90">http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VCfZypSSz90</a>

Greg Bennett CBCD 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.